🏛️ Verified NIH Record • Updated 2026-04-22
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (NCT04913285)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Pierre Fabre Medicament
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (8 items).
Location: The Angeles Clinic — Los Angeles, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)
- In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.
- GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.
- Active, uncontrolled bacterial, fungal, or viral infection.
- Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded
- Women who are lactating or breastfeeding, or pregnant.
- Participants with any other active treated malignancy within 3 years prior to enrollment Complete inclusion and exclusion criteria are listed in the clinical study protocol.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (50 Sites)
- The Angeles Clinic — Los Angeles, California
- UCLA — Los Angeles, California
- University of California San Diego, Moores Cancer Center — San Diego, California
- University of California San Francisco — San Francisco, California
- Stanford Cancer Center — Stanford, California
- Sarah Cannon Research Institute Denver — Denver, Colorado
- Mayo Clinic - Florida — Jacksonville, Florida
- Sarah Cannon Research Institute - Florida Cancer Specialists — Orlando, Florida
- Mayo Clinic - Rochester — Rochester, Minnesota
- Atlantic Health — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic — Cleveland, Ohio
- Sarah Cannon Research Institute-Tennessee Oncology — Nashville, Tennessee
- MD Anderson — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Calvary Mater Hospital Newcastle — Waratah, New South Wales
- Melanoma Institute Australia — Wollstonecraft, New South Wales
- Tasman Health Care — Southport, Queensland
- Austin Health — Heidelberg, Victoria
- Linear Clinical Research — Perth, Western Australia
- Harbin Medical University Cancer Hospital — Haerbin, Heilongjiang
- Linyi Cancer Hospital — Linyi, Shandong
- Beijing University Cancer Hospital — Beijing,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.